Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Pharmaceutical Technology
APRIL 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
Pharmaceutical Technology
APRIL 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
Rethinking Clinical Trials
MARCH 6, 2024
Schell Professor of Management and Applied Economics MIT Sloan School of Management Slides Keywords Food-as-Medicine, Randomized Clinical Trial, Diabetes Key Points Diabetes is common and costly. Food insecurity is associated with diabetes. Speaker Joseph Doyle, PhD Erwin H. 9% of the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JULY 19, 2023
The objective of COORDINATE-Diabetes trial was to improve the implementation and adoption of these therapies by testing the impact of a clinic-level, multifaceted intervention on the prescription of 3 key groups of evidence-based therapies. in which participants had type 2 diabetes mellitus and ASCVD.
Pharmaceutical Technology
JANUARY 17, 2023
Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. Mounjaro is anticipated to launch in the US later this year or by early 2024.
XTalks
NOVEMBER 3, 2022
Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). In the third quarter of 2022, Mounjaro scored $187.3
Rethinking Clinical Trials
DECEMBER 6, 2022
Pragmatic Clinical Trials, Heart Failure, Diabetes. that focused on patients with heart failure and diabetes, two rapidly growing conditions that are highly morbid. The post Grand Rounds December 2, 2022: A Randomized Controlled Trial of Mobile Health Intervention in Heart Failure and Diabetes: Lessons Learned (G. Key Points.
XTalks
APRIL 29, 2022
Tirzepatide was previously shown to reduce weight in diabetic individuals, and now, results from Lilly’s trial exclusive to obesity show that it can help people without diabetes lose significant pounds. Related: Eli Lilly’s Type 2 Diabetes Shot Tirzepatide Emerges Winner Against Semaglutide.
Let's personalize your content